Tumor cells can evade immune detection by downregulating commonly recognized antigens, presenting a major challenge for effective immunotherapy. In this first-in-human study, the authors showed that the activation of T cells recognizing a new class of tumor antigens presented by immunotherapy-escaped tumor cells is safe and may lead to clinical benefit.
- Mitchell Emmers
- Marij J. P. Welters
- Sjoerd H. van der Burg
